Skip to main content
. 2018 Apr;365(1):60–71. doi: 10.1124/jpet.117.245746

Fig. 2.

Fig. 2.

TLR9 agonist ODN2395 does not impair SERCA2 activity, unlike classic SERCA2 inhibitor thapsigargin, or promote TLR9-SERCA2 colocalization in vascular tissues. In denuded MRAs incubated in vehicle (Veh), ODN2395 (2 μmol/l), or thapsigargin (1 μmol/l), contractile responses were measured during calcium loading (A), after intracellular calcium release (B), and in the time to achieve maximum relaxation after NE washout (C). ATP concentration was measured in isolated microsomes (n = 5; 8 pooled aortae/sample), incubated in either vehicle or ODN2395, with or without thapsigargin, across a 60-minute time course (D) and summated as the AUC (E). (F) Coimmunoprecipitation was performed for TLR9 with SERCA2 in MRAs incubated with vehicle or ODN2395 (n = 3; 2 pooled MRAs/sample). (G) Protein expression analysis was performed for phospho (p)-AMPKαThr172 normalized to total AMPKα in MRAs incubated with vehicle or thapsigargin. Above, representative images of immunoblots; below, densitometric analysis. n = 3–6. One-way ANOVA, *P < 0.05 vs. vehicle; two-way ANOVA, *P < 0.05 vs. vehicle, #P < 0.05 vs. ODN2395.